GMAB.DK

1,581.5

+3.88%↑

COLO.B.DK

383.8

+1.29%↑

HLUNB.DK

44.56

+1.41%↑

ZEAL.DK

332

+10.96%↑

AMBUB.DK

66.35

+3.67%↑

GMAB.DK

1,581.5

+3.88%↑

COLO.B.DK

383.8

+1.29%↑

HLUNB.DK

44.56

+1.41%↑

ZEAL.DK

332

+10.96%↑

AMBUB.DK

66.35

+3.67%↑

GMAB.DK

1,581.5

+3.88%↑

COLO.B.DK

383.8

+1.29%↑

HLUNB.DK

44.56

+1.41%↑

ZEAL.DK

332

+10.96%↑

AMBUB.DK

66.35

+3.67%↑

GMAB.DK

1,581.5

+3.88%↑

COLO.B.DK

383.8

+1.29%↑

HLUNB.DK

44.56

+1.41%↑

ZEAL.DK

332

+10.96%↑

AMBUB.DK

66.35

+3.67%↑

GMAB.DK

1,581.5

+3.88%↑

COLO.B.DK

383.8

+1.29%↑

HLUNB.DK

44.56

+1.41%↑

ZEAL.DK

332

+10.96%↑

AMBUB.DK

66.35

+3.67%↑

Home・Aktien・Novo Nordisk A-S (Class B)

Novo Nordisk A-S (Class B)

Open

283.7 4.34

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

273.2

Max

284.15

Schlüsselkennzahlen
By Trading Economics
Einkommen	22B 49B
Verkäufe	18B 97B
KGV Branchendurchschnitt	10.261 49.888
EPS	10.91
Dividendenrendite	4.11
Gewinnspanne	50.15
Angestellte	67,900
EBITDA	32B 69B

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+9.53% upside

Dividenden
By Dow Jones
Dividendenrendite Branchendurchschnitt	4.11% 2.38%
Nächstes Ergebnis	5. Aug. 2026
Nächstes Ex-Dividendendatum	13. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-8.3B 1.2T
Vorheriger Eröffnungskurs	279.36
Vorheriger Schlusskurs	283.7

Novo Nordisk A-S (Class B) Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

11. Mai 2026, 15:48 UTC

Akquisitionen, Fusionen, Übernahmen

Novo Nordisk to Sell Parkinson's Cell Therapy to Startup Cellular Intelligence

6. Mai 2026, 07:30 UTC

Ergebnisse

Wegovy Maker Novo Nordisk Lifts Guidance Following Strong Launch of Weight-Loss Pill -- Update

6. Mai 2026, 06:19 UTC

Ergebnisse

Wegovy Maker Novo Nordisk Lifts Guidance Following Strong Launch of Weight-Loss Pill

3. Juni 2026, 09:48 UTC

Market Talk

Novo Nordisk's UAE Wegovy Pill Launch an Important Step -- Market Talk

29. Mai 2026, 23:06 UTC

Akquisitionen, Fusionen, Übernahmen

After a Series of Sales, Hims Director Buys Company Shares -- Barrons.com

18. Mai 2026, 13:10 UTC

Market Talk

Ergebnisse

Novo Nordisk Report Shows Bright Spots Amid Price Pressure -- Market Talk

12. Mai 2026, 12:05 UTC

Heiße Aktien

Stocks to Watch: GameStop, Venture Global, Wendy's, Hims & Hers -- WSJ

12. Mai 2026, 10:51 UTC

Heiße Aktien

Stocks to Watch: GameStop, Venture Global, Hims & Hers, GoPro -- WSJ

12. Mai 2026, 09:42 UTC

Ergebnisse

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

12. Mai 2026, 09:08 UTC

Heiße Aktien

Stocks to Watch: Venture Global, Hims & Hers, GoPro -- WSJ

11. Mai 2026, 20:30 UTC

Ergebnisse

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

7. Mai 2026, 09:30 UTC

Ergebnisse

America's Weight-Loss Drug Boom Is Going Global -- Heard on the Street -- WSJ

6. Mai 2026, 12:36 UTC

Ergebnisse

Novo's Weight-Loss Pill Heaps Pressure on Eli Lilly. Stock Jumps After Earnings. -- Barrons.com

6. Mai 2026, 10:53 UTC

Heiße Aktien

Stocks to Watch Today: Advanced Micro Devices, Samsung, Disney -- WSJ

6. Mai 2026, 10:12 UTC

Ergebnisse

Novo Stock Rises After Earnings. It's Taking the Weight-Loss Drug Fight to Eli Lilly. -- Barrons.com

6. Mai 2026, 09:58 UTC

Ergebnisse

Novo Nordisk Shares Jump on Strong Demand for Wegovy Pill -- 2nd Update

6. Mai 2026, 09:35 UTC

Heiße Aktien

Stocks to Watch Today: Advanced Micro Devices, Samsung, Disney -- WSJ

6. Mai 2026, 08:13 UTC

Market Talk

Ergebnisse

Novo Nordisk Guidance Tweak Unlikely to Drive Upgrades -- Market Talk

6. Mai 2026, 07:43 UTC

Market Talk

Ergebnisse

Novo Nordisk Consensus Earnings Expectations Likely to Rise -- Market Talk

6. Mai 2026, 07:00 UTC

Ergebnisse

Novo Nordisk Shares Rise 5.5% After 1Q Results

6. Mai 2026, 06:34 UTC

Ergebnisse

Novo Nordisk Execs Were Speaking on Media Call After 1Q Earnings

6. Mai 2026, 06:26 UTC

Ergebnisse

Novo Nordisk CFO: Branded GLP-1 Market is Expanding

6. Mai 2026, 06:26 UTC

Ergebnisse

Novo Nordisk CFO: Data Indicates There is a Lower Share of Compounders in The Market

6. Mai 2026, 06:24 UTC

Ergebnisse

Novo Nordisk CFO: Believe We've Found a Sweet Spot in Terms of Pricing With Wegovy Pill

6. Mai 2026, 06:20 UTC

Ergebnisse

Novo Nordisk CEO: Very Excited By What We See With Wegovy Pill

6. Mai 2026, 06:19 UTC

Ergebnisse

Novo Nordisk CFO: So Far Competitor's Pill Hasn't Impacted Wegovy Pill Trajectory

6. Mai 2026, 06:13 UTC

Ergebnisse

Novo Nordisk CEO: Continue To Try and Improve Our Pipeline Internally and Externally

6. Mai 2026, 06:13 UTC

Ergebnisse

Novo Nordisk CEO: Seen Continued Interest In Our Pill Despite Competitor Entering Market

6. Mai 2026, 06:12 UTC

Ergebnisse

Novo Nordisk CFO: Impact From Higher Oil Prices is Immaterial to Co

6. Mai 2026, 05:43 UTC

Ergebnisse

Novo Nordisk: Total Wegovy Pill Prescriptions Since Launch Now Exceed 2M

Peer-Vergleich

Kursveränderung

Novo Nordisk A-S (Class B) Prognose

Kursziel

By TipRanks

9.53% Vorteil

12-Monats-Prognose

Durchschnitt 1,162.73 DKK 9.53%

Hoch 1,550 DKK

Tief 720 DKK

Basierend auf 11 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Novo Nordisk A-S (Class B) – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

11 ratings

Buy

Halten

Sell

Basierend auf 11 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Novo Nordisk A-S (Class B) – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Novo Nordisk A-S (Class B)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.